Cargando…

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study

OBJECTIVES: Two biomarkers, growth differentiation factor 15 (GDF-15) and fibroblast growth factor 23 (FGF-23)), reflecting different aspects of renal pathophysiology, were evaluated as determinants of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular disease (CVD) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frimodt-Møller, Marie, von Scholten, Bernt Johan, Reinhard, Henrik, Jacobsen, Peter Karl, Hansen, Tine Willum, Persson, Frederik Ivar, Parving, Hans-Henrik, Rossing, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919646/ https://www.ncbi.nlm.nih.gov/pubmed/29698460 http://dx.doi.org/10.1371/journal.pone.0196634

Ejemplares similares

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
por: Rossing, Peter, et al.
Publicado: (2021)

Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2015)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes
por: Stougaard, Elisabeth Buur, et al.
Publicado: (2021)

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria
por: Poulsen, Christina Gjerlev, et al.
Publicado: (2023)

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions
por: Eickhoff, Mie Klessen, et al.
Publicado: (2020)

Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study
por: Theilade, Simone, et al.
Publicado: (2013)

Effect of large weight reductions on measured and estimated kidney function
por: von Scholten, Bernt Johan, et al.
Publicado: (2017)

Mitigating risk of aldosterone in diabetic kidney disease
por: Frimodt-Møller, Marie, et al.
Publicado: (2020)

Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease
por: Persson, Frederik, et al.
Publicado: (2019)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
por: Zobel, Emilie H., et al.
Publicado: (2021)

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
por: Currie, Gemma E., et al.
Publicado: (2018)

Carotid‐Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus
por: Tougaard, Ninna Hahn, et al.
Publicado: (2020)

Phosphate and fibroblast growth factor 23 in diabetes
por: van der Vaart, Amarens, et al.
Publicado: (2021)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
por: Reinhard, Henrik, et al.
Publicado: (2011)

NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Fibroblast growth factor 23 and bone mineralisation
por: Guo, Yu-Chen, et al.
Publicado: (2015)

Physiological Actions of Fibroblast Growth Factor-23
por: Erben, Reinhold G.
Publicado: (2018)

Upstream Regulators of Fibroblast Growth Factor 23
por: Ratsma, Danielle M. A., et al.
Publicado: (2021)

Fibroblast growth factor 23, klotho and heparin
por: Thomas, S. Madison, et al.
Publicado: (2023)

Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate
por: Joergensen, Christel, et al.
Publicado: (2012)

Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer
por: Ghorbanihaghjo, Amir, et al.
Publicado: (2018)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Wang, Joseph, et al.
Publicado: (2017)

Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy
por: Vestergaard, Mark B., et al.
Publicado: (2023)

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
por: Persson, Frederik, et al.
Publicado: (2009)

Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism
por: Saito, Tasuku, et al.
Publicado: (2009)

PKC regulates the production of fibroblast growth factor 23 (FGF23)
por: Bär, Ludmilla, et al.
Publicado: (2019)

The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
por: Heijboer, Annemieke C., et al.
Publicado: (2022)

Fibroblast Growth Factor–23 and Cardiac Structure and Function
por: Agarwal, Isha, et al.
Publicado: (2014)

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia
por: Czaya, Brian, et al.
Publicado: (2019)

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
por: Reinhard, Henrik, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3k310gos38ebub2rcn1517tvm0